Humana 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Humana said 2026 performance to date is better than initial guidance, with cost trends in line to better than expectations for new and existing members.
- Management increased its full-year adjusted EPS outlook from at least $9 to at least $9.50 and said it remains on track to double individual MA pretax margin this year, excluding the STARS headwind.
- Humana reported a member-weighted star rating of 4.17 for BY28, with 663,000 more care opportunities met, 534,000 additional members completing an annual preventative visit, and improved screening and detection outcomes compared with the prior year.
- Medicaid membership grew by 104,000 members in 2026, while CenterWell Primary Care added nearly 147,000 members, or 30% growth, including the acquisition of MaxHealth in the first quarter.
- Humana expects to complete the divestment of its minority interest in Gentiva this quarter for approximately $900 million in total pretax proceeds.
- The newly announced and closed BlackRock joint venture replaces the previous longstanding JVs with Welsh Carson; Humana expects it to reduce the GAAP debt-to-CAP ratio by approximately 130 basis points in the 4th quarter.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, and thank you for standing by. Welcome to Humana's third quarter 2026 earnings call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star, one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star, one again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to Lisa Stoner, Vice President of Investor Relations.
Please go ahead. Thank you, and good morning.
We will begin this morning with brief remarks from Jim Rechtin, Humana's President and Chief Executive Officer, and Chief Financial Officer Celeste Mellet. Following these remarks, we will host a question-and-answer session with industry analysts. Before we begin our discussion, I need to advise call participants of our cautionary statement. Certain of the matters discussed in this conference call are forward-looking and involve a number of risks and uncertainties. Actual results could differ materially. Investors are advised to read the detailed risk factors discussed in our latest Form 10-K, our other filings with the Securities and Exchange Commission, and our third quarter 2026 earnings press release, as they relate to forward-looking statements, along with other risks discussed in our SEC filings. We undertake no obligation to publicly address or update any forward-looking statements in future filings or communications regarding our business or results.
Today's press release and posted remarks, our historical financial news releases, and our filings with the SEC are all also available on our investor relations site. Call participants should note that today's discussion includes financial measures that are not in accordance with generally accepted accounting principles, or GAAP. Management's explanation for the use of these non-GAAP measures and reconciliations of GAAP to non-GAAP financial measures are included in today's press release. Any reference to earnings per share, or EPS, made during this conference call refer to diluted earnings per common share. Finally, this call is being recorded for replay purposes. That replay will be available on the investor relations page of Humana's website, humana.com, later today. With that, I'll turn it over to Jim.
Thank you, Lisa. Good morning, everyone, and thank you for joining us. We have just one headline today, and that is that we are in a good place. Execution is strong and improving. Signs point to our strategy working. We are increasingly seeing the tangible results of our team's good work. The results are positive for our members, our patients, and their health, and the results are contributing to our margin and earnings growth recovery, which is moving from on plan towards being ahead of plan. As usual, I will frame my comments today around the four drivers of our business. One, product and experience, which drive customer retention and growth. Two, clinical excellence, which delivers clinical outcomes and medical margin. Three, highly efficient operations. Four, capital allocation and growth in both CenterWell and Medicaid. Let's start with product and experience.
Our 2026 membership, both new and returning, is performing in line to better than expected. Our 2027 product positioning also appears to be in line with expectations. Our product portfolio positions us largely as we expected at the time of bids. We believe our portfolio will deliver the margin progression in 2027 that is necessary to put us on track for a 3% plus margin in 2028. Importantly, our portfolio is focused on providing our members simple, affordable, and predictable coverage. It does this by protecting the benefits and services that seniors consistently identify as most important. So far, AEP performance is ahead of our initial expectations. Our recapture or retention of our members impacted by plan exits has been particularly strong, but we are also seeing new sales ahead of plan.
While it remains very early in AEP, we currently anticipate that our membership will be up for 2027. Turning to clinical excellence, I am just going to say again that we are thrilled with our bonus year 2028, or BY28, results. Our STARS ratings approach the highest ratings Humana has ever achieved, with a member-weighted STARS rating of 4.17. I am proud of this team. This is truly the result of 65,000 associates working together to drive better experiences and health outcomes for our members. I am going to provide just a few examples to bring this to life. Compared with the prior year, 663,000 more care opportunities were met, 534,000 additional members completed an annual preventative visit, 28,000 members received an overdue mammogram. This allowed us to identify 600 previously undetected breast cancers, many at an earlier stage than they otherwise would have been found.
93,000 members completed an overdue colorectal cancer screening. This allowed us to identify 100 previously undetected cases of pre-cancers and cancers. 73,000 members living with diabetes received an overdue eye exam. This allowed us to identify 17,000 previously undetected diagnoses of diabetes-related eye disease, which is a leading cause of vision loss. Detecting these conditions early is critical to successfully treating them and managing the conditions. The improvement that the team has driven in the STARS program over the last two years is truly remarkable, and it is driving a real difference for our members. From a financial perspective, as we shared in the eight-K and audio file in October, our BY28 results significantly exceed our goal of top quartile. As a reminder, results at roughly top quartile is the level of STARS performance that we believe is necessary to sustain a 3% margin and have competitive product.
At or near top quartile performance is what is sustainable on an ongoing basis. We will have years close to top quartile, we will have years slightly above top quartile, and we will have years like this year well above top quartile. However, we will manage the business assuming a level that approximates top quartile. That means our benefit structure and our broader cost structure must be tuned to and work closer to top quartile results, not at top decile. As a result, we anticipate a one-time tailwind in 2028. We expect to utilize some of this tailwind for one-time investments. These investments will help solidify our STARS capability and accelerate our efforts to improve the customer experience and improve clinical outcomes. We also expect additional one-time return to shareholders. We do not believe we can productively invest the full tailwind, and thus we will pass some through to shareholders.
Once we have more information on 2028, which includes competitive dynamics, membership and product dynamics, and regulatory environment, we will quantify the level of and the expected use of the tailwind. We will size how much we will invest, and we will explain roughly how much we will pass through to earnings. Turning to BY29 STARS, we continue to drive strong operational performance, running roughly 5% ahead of last year's quality improvement rate on a per-member basis in key HEDIS metrics at the end of Q3. We feel confident that we will achieve our goal of top quartile performance for BY29. Regarding highly efficient operations, our multi-year transformation is progressing as anticipated, and we look forward to providing a more detailed update on this work at a December investor event. Finally, let me turn to capital allocation.
I will start with Medicaid, where we have implemented contracts in six new states over the last three years, with our Medicaid footprint now spanning 13 states, including 11 active states and contracts awarded with implementations pending in Georgia and Texas. Our Medicaid membership has grown by 104,000 members in 2026, largely driven by the start of the Michigan HIDE-SNP and the statewide Illinois FIDE-SNP programs, as well as the carve-in of dual eligibles in the South Carolina Medicaid program. We are excited about these integrated dual programs, and we believe we are uniquely capable of delivering great outcomes for members and for states. Within CenterWell Primary Care, we have driven strong growth this year, adding nearly 147,000 members, or 30% growth, including the acquisition of MaxHealth in the first quarter. And we recently established a new partnership with BlackRock, which we are very excited about.
Celeste will touch on this more in a moment. In conclusion, we are driving strong execution across the company, which has us on a positive trajectory. We are pleased with our 2026 performance to date and our increased full-year outlook. We are incredibly proud of our BY28 STARS results and expect to maintain top quartile results for BY29. We are positioned as we expected for the 2027 AEP, and we expect to make meaningful progress on MA margin expansion next year. And finally, we remain on track to deliver on our Investor Day commitments in 2028, which we will mark to market for you at the investor update on December 10th. With that, I will turn it to Celeste for a few remarks before Q&A.
Thank you, Jim. I will touch on our 2026 performance and improved full-year EPS outlook before providing more detail on our continued balance sheet efficiency and capital optimization progress, including the recently announced JV with BlackRock. Starting with 2026, based on available information to date, cost trends are in line to better than our expectations for both new and existing members. Our performance to date supports an increase in our full-year adjusted EPS outlook from at least $9 to at least $9.50. We also continue to maintain and build prudent reserves, with IBNR up sequentially, despite the seasonal shift where pharmacy costs make up a greater proportion of total benefit costs as we move through the year. All in, we are executing and delivering results better than initial guidance and remain on track to double our individual MA pre-tax margin this year, excluding the STARS headwind.
Turning to the balance sheet, we have continued our efforts to increase the efficiency of the balance sheet and fortify our foundation, and our significant progress reflects relentless focus on execution. We expect two major transactions to close this quarter. First, we will complete the divestment of our minority interest in Gentiva. Total pre-tax proceeds will be approximately $900 million. In addition, we recently announced and closed a new joint venture with BlackRock, which replaces the previous longstanding JVs with Welsh Carson. Our new JV has substantially enhanced our balance sheet efficiency and increased our financial flexibility, while significantly reducing our cost of capital, reflecting the maturity of the business. With the new structure, we will have the option to purchase clinics from the JV beginning in 2028.
If we have not acquired all of the clinics by the end of 2033, BlackRock will have the right to exit the JV through a sale process, and we have the right to submit the first offer to acquire any remaining clinics. Importantly, the significantly reduced cost of capital under the new arrangement drives a substantial reduction of the JV-related liabilities on the balance sheet. We anticipate that this transaction will drive a reduction of approximately 130 basis points in the GAAP debt-to-cap ratio in the fourth quarter. Further, we no longer need to fund the previously pending put option in 2027, which, if debt-funded, would have increased our debt-to-cap ratio by approximately 130 basis points next year, all else equal. We will continue to evaluate a pipeline of initiatives to drive further efficiency and resiliency. Before going to Q&A, let me reiterate the headline that Jim shared.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
15 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
